Get more replies from employers
Send a job-specific resume in minutes.
Sutro Biopharma, Inc. is seeking a Senior Scientist, Formulation and DP Development to lead formulation and DP development for biologics and conjugates, and to create robust DP manufacturing processes to advance our pipeline in a fast-paced environment.
You will design and execute stability and in‑use studies, implement fit‑for‑purpose analytical methods for protein characterization, and collaborate with upstream/downstream teams and CMOs to ensure successful tech transfer and regulatory
Sutro Biopharma, Inc. is looking for a technical leader who will report to the Executive Director of Formulation and DP Development. You will be developing new compositions for biologic / conjugated molecules and creating robust DP manufacturing processes to advance Sutro pipeline and enhance our internal and collaborative product development initiatives in a fast‑paced environment.
Anticipated salary range for fully qualified candidates applying for this role at Sutro Biopharma’s California based locations will be $155,000 - $168,000 (not including bonus, equity, and benefits). The final salary offered will be dependent on several factors that include and are not limited to relevant previous experience, job responsibilities and duration of experience, the type and length of experience within the industry and education.
Sutro Biopharma is an equal opportunity employer. We believe in fostering a culture that is inclusive and values diversity in background and opinions. Our company progresses without regard to race, ethnicity, gender, sexual orientation, religious belief, age, disability or citizenship status. We are dedicated to creating a safe environment where employees can grow and succeed together.
We encourage all colleagues to be fully vaccinated for COVID‑19 prior to the first date of employment.
Sutro Biopharma, Inc. is advancing a next‑generation antibody‑drug conjugate (ADC) platform designed to deliver single‑ and dual‑payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell‑free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual‑payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy.